🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🙂 Very Happy to share this comprehensive review on AML, from an MD Anderson Cancer Center perspective, discussing all that is new and exciting in the field 🩸 Hagop Kantarjian,MD ➡️ Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges ACS

The OncoAlert🚨Newsletter Now Out Covering March 14-20, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅🫁🔑❄️ ✅Fertility Preservation Guidelines ASCO 🤰 ✅ #LITESPARK in #KidneyCancer ✅ #KEYNOTE921 🔑 in #ProstateCancer ✅ #ADAURA 🫁 in

Check out our comprehensive review on #AML from an MD Anderson Cancer Center perspective, " Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges" published in ACS Journal Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #leusm

Behind the scenes 🎬 Stay tuned for the MD Anderson Cancer Center Cancerwise Podcast on #MRD with Naveen Pemmaraju, MD #leusm #leukemia #BPDCN

➡️ Excited to share the phase 1b/2 clin trial of Aza-Ven-Magro in ND high-risk & R/R AML from MD Anderson Cancer Center led by Naval Daver, M.D., just out in Clinical Cancer Research ✅ Interesting correlative analysis by Hussein Abbas interrogating mech of Magro resistance in TP53-mut AML ✅Despite

Dear Leukemia friends, making U aware of this exceptional MDS symposium organized by Dr. simona colla at MD Anderson Cancer Center in May 2025! The speaker line up is phenomenal & the science is cutting edge. Register 👇🏼 join us & RT pls mdanderson.cloud-cme.com/course/courseo… #MDSsm

➡️ How often are we able to transplant responding patients with TP53-mut AML? ➡️ We tried to understand outcomes and barriers to HSCT in responding patients <70 y/o with TP53-mut AML ✅ just published in Bone Marrow Transplantation 📄nature.com/articles/s4140… ➡️ Novel regimens which garner

First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies ACS Journal Cancer doi.org/10.1002/cncr.3…

Historical development, current status, and future research of olverembatinib, a new third-generation BCR::ABL1 TKI with significant activity and favorable safety profile: MD Anderson Cancer Center #Leukemia Fadi Haddad, MD dx.doi.org/10.1002/cncr.3… #leusm #CML

WBC >70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation jhoonline.biomedcentral.com/articles/10.11… #leusm #ALL

Don't miss another episode of Oncology #Here and #Now a Webcast/Podcast 🎙️put out by OncoAlert 🚨feat my #AF colleague Bárbara Melão, MD, PhD and Dr. Philippe Spiess Philippe spiess on #GUonc #OncoAlertAF Emre Yekedüz Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Erman Akkus Bárbara Melão, MD, PhD Alizée Camps - - Maléa

Check out the latest OncoAlert 🚨ROUND UP - May 15-22, 2025 - REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… This week reviewing: ✅Systemic tx for HR+/HER2- early stage and metastatic #BreastCancer ✅Hypofractionated, Dose-Escalated Radiation Versus

🎊Congratulations Elise Nassif Haddad for receiving the "Teaching Department of the Year" at the #Hemonc Fellowship Ceremony on behalf of the #Sarcoma Medical Oncology Department at MD Anderson Cancer Center under the leadership of Neeta Somaiah, MD 🥇

Happy to be part of the #MENA 2025 regional meeting in #Lebanon 🇱🇧 organized by the BEST Hampig Kourie to discuss ⤵️ 1️⃣ Evolving Management of Acute Myeloid #Leukemia 2️⃣ Management of Toxicities of Bispecifics and ADCs in #Hematological Malignancies #leusm #science #education

#ASCO25 was different this year with Alexandre joining us, as the youngest ASCO attendee 👶 📢 Shoutout to Elise Nassif Haddad & all working mothers who navigate everyday the scientific & medical field while taking care of their families 🥇

👏 Congratulations Ryan Denu, MD, PhD on your oral presentation at #ASCO25 🥇Great to see Elise Nassif Haddad from MD Anderson Cancer Center chairing fhe #sarcoma session this morning at ASCO

Dear Colleagues, an honor to introduce our colleague Miguel Zugman of City of Hope Discussing his poster at #ASCO25 on Long-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC) #KidneyCancer

Always a pleasure & fun to bump into Dr. Islam Sadek at ASCO Truly amazing person, putting all efforts to improve outcomes in #leukemia & enhance collaborations between HCPs, patients, institutions,... #ASCO25 #CML

Dear Colleagues at #ASCO25 An honor to present Angela Toss Presenting on Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with #BreastCancer Eva Blondeaux Cynthia Villarreal-Garza, MD DSc Carmine De Angelis Elisa Agostinetto Breast Cancer

📢 Out at ASCO Updates on the management of frontline #CML with a particular focus on #cost & the interplay between pharma, patients, & intermediaries ⤵️ #leukemia #ASCO25 Hagop Kantarjian,MD Journal of Clinical Oncology OncoAlert ascopost.com/news/may-2025/…